Asensus Surgical Inc (AMEX:ASXC) does about 2.59M shares in volume on a normal day but saw 21599692 shares change hands in the recent trading day. The company now has a market cap of 94.32M USD. Its current market price is $0.35, marking an increase of 15.62% compared to the previous close of $0.30. The 52 week high reached by this stock is $0.40 whilst the lowest price level in 52 weeks is $0.17. The script in recent trading has seen the stock touch a high of $1.5 and a low of $1.5.
Asensus Surgical Inc (ASXC) has a 20-day trading average at $0.3203 and the current price is -13.42% off the 52-week high compared with 104.56% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.3282 and its 200-day simple moving average is $0.2856. If we look at the stock’s price movements over the week, volatility stands at 24.24%, which decreases to 7.39% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 62.45 to suggest the stock is neutral.
2 analysts observing the Asensus Surgical Inc (ASXC) stock have set the 12-month price targets for the company’s shares at between $1.5 and $1.5. The consensus objective for the share price is $0.35. The median price target is 76.67% away from the current levels at $1.5.
FactSet Research has provided data showing that 2 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 1 analysts have rated it as a buy and 1 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Hold the stock.
H.C. Wainwright initiated its price target at $4.
The current price level is 8.04%, 5.42%, and 21.33% away from its SMA20, SMA50, and SMA200 respectively, with the ASXC price moving below the 50-day SMA on current market day. Asensus Surgical Inc (ASXC) stock is up 8.00% over the week and 1.83% over the past month. Its price is 8.40% year-to-date and 17.99% over the past year.
Its 12-month price target is $1.5. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $1.5, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $1.5.
Outstanding shares total 272.84M with insiders holding 2.06% of the shares and institutional holders owning 18.27% of the company’s common stock. The company has a return on equity of -334.02%. The beta has a value of 1.32. Price to sales ratio is 9.58.
